Plain-English translation of NCT07174063 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase 1 trial is testing a new medication called (luxdegalutamide) in men with metastatic prostate cancer—cancer that has spread beyond the prostate to bones or organs. The study will look at how safe the medication is, how well patients tolerate it, and how the body processes it. About 6 Japanese men will participate.
Men with advanced prostate cancer that no longer responds to standard treatments need new options. This medication is designed to target prostate cancer in a new way, and this early-stage study will help doctors understand whether it's safe enough to test further.
You would take the medication by mouth once a day, starting at 300 mg (though the dose might be lowered to 100 mg if needed). You'll continue taking it until your cancer progresses, side effects become too severe, or you decide to stop. You'll have regular check-ins and imaging scans to monitor how you're doing, plus visits within 7 days and 30 days after you finish the medication to check for any lingering effects.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
Japan
Phase
Safety & dosing
Sponsor
Novartis Pharmaceuticals
Enrollment target
~6 participants
Started
November 2025
Primary completion
January 2027
Age range
18 Years – 100 Years
Sex
Male only
Last updated on clinicaltrials.gov in July 2026.